Global Kidney Cancer Drugs Market 2015-2019

News provided by

Jul 23, 2015, 06:47 ET

DUBLIN, July 22, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/n57vgj/global_kidney) has announced the addition of the "Global Kidney Cancer Drugs Market 2015-2019" report to their offering.

The global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.

Logo

The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer. The report also includes a discussion of the key vendors operating in this market.

Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer. For instance, Avastin (bevacizumab) in combination with interferons slows the proliferation of the disease. Combination drugs are selected depending upon the health condition of the patient and the severity of the disease. Combinations of IL-2 with interferons were more effective than IL-2 or interferon alone. Many other combination therapies are currently under investigation. For example, TRACON Pharmaceuticals is engaged in the phase II development of TRC-105 in combination with Inlyta for the treatment of RCC.

According to the report, the prevalence of kidney cancer worldwide has increased in recent years. Changes in lifestyle, increased consumption of alcohol, excessive smoking, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Apart from these, the growing elderly population also results in a high incidence of the disease, as kidney cancer usually affects individuals aged 45 and above. In addition, the prevalence of the disease was higher in developed countries than in developing nations. These factors together account for a steady rise in the patient population opting for kidney cancer medication.

Further, the report states that a limited number of approved drugs for the treatment of kidney cancer are present in the market.

Key Vendors